Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Produced in partnership with advocate, journalist and filmmaker Jasmine IVANNA Espy, "The Beacons: Illuminating HS Stories" offers an intimate look...
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with...
The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis...
Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1...
Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult ...
Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for...
RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral...
Novartis commits additional $17.7 million to create Clinical Trial Centers of Excellence at Howard University College of Medicine, Meharry Medical...
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a...
FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive...
Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx®...
- Con dos dosis de mantenimiento al año, Leqvio es el primer y único tratamiento de ARN de interferencia pequeño (ARNip) aprobado por la FDA para la...
Novartis 今天宣布,美国食品药品监督管理局 (FDA) 批准 Leqvio® (inclisiran),这是第一款也是唯一一款用于降低低密度脂蛋白胆固醇(也称为坏胆固醇或 LDL-C)的小干扰 RNA (siRNA) 疗法,在给予初始剂量和第三个月的一剂给药后,可每年两次给药。...
Novartis 今日宣布美國食品藥物管理局(FDA)核准 Leqvio® (inclisiran),這是第一個也是唯一一個小型干擾 RNA(siRNA)療法,用於降低低密度脂蛋白膽固醇(也稱為壞膽固醇或 LDL-C),在初始劑量和三個月後再給予一劑之後,每年僅需兩劑。 Novartis 總裁...
Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) ...
Novartis today announced new Piqray® (alpelisib) data indicating benefit across a broad range of patient and disease characteristics as seen in...
Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine therapy...
Novartis today announced that a Phase II study of investigational iptacopan (LNP023) – a first-in-class, oral, selective factor B inhibitor – in...
Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an...
Novartis today announced the launch of "Meet The PROS," an initiative to raise awareness and offer new educational resources for PIK3CA-Related...
Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor...
Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu)...
Novartis today announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of...
Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in postmenopausal...
Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx®...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.